No Data
No Data
Yifan Pharmaceutical (002019): The risk of impairment has been cleared, and the inflection point of significant growth of its own products has arrived
Incident: April 20, 2023, the company released its 2023 annual report. In 2023, the company achieved revenue of 4,068 billion yuan, an increase of 6.03% over the previous year; net profit to mother was 551 million yuan. April 2, 2023
Yifan Pharmaceutical (002019): 2023 results are in line with expectations, and both revenue and profit growth accelerated in 2024Q1
Incident The company issued an announcement for 2023, with revenue of 4,068 billion yuan, up 6.03% year on year; net profit due to mother - 551 million yuan, up 388.19% year on year; net profit not attributable to mother - 533 million yuan, year on year
Yifan Pharmaceutical (002019) Quarterly Report Review: The inflection point of performance has reached a rapid growth rate that exceeds market expectations and the growth of the main pharmaceutical industry is driving volume
The 2024 quarterly report was released. The company achieved operating income of 1.3 billion yuan (+41.28% year-on-year, same below) and net profit to mother of 146 million yuan (+125.55%) in Q1 2024, after deducting net profit of non-attributable net profit1
Yifan Unit's Allergy Drug Passes China Regulatory Test, Stock Price Jumps
Yifan Pharmaceutical (SHE:002019) unit Sichuan Defeng Pharmaceutical's emestine fumarate sustained-release capsules passed the consistency evaluation by China's National Medical Products Administratio
Yifan Pharmaceutical's Unit Gets Nod to Register Nimodipine Injection
Yifan Pharmaceutical's (SHE:002019) unit, Liaoning Yifan Pharmaceutical, received a drug registration certificate from China's National Medical Products Administration for its nimodipine injection, th
Three Drugs of Yifan Pharmaceutical's Unit Placed in China's Centralized Procurement
Three drugs produced by Yifan Pharmaceutical's (SHE:002019) unit, Hefei Yifan Biopharmaceutical, were included in China's National Centralized Drug Procurement, the company said in its filing on the S
No Data